Navigation Links
Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
Date:8/23/2007

NATICK, Mass., Aug. 23 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has successfully amended its $2 billion revolving line of credit and $5 billion term loan agreement, providing the Company additional financial flexibility as it implements initiatives designed to increase shareholder value.

"We were pleased to work with our lenders to amend our credit facility," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "These changes provide significant financial flexibility that will assist us as we execute our plan to divest non-strategic assets, monetize our investment portfolio, and reduce expenses and head count, as well as achieve our broader goal of increasing shareholder value."

Among other items, the amendment extends a step-down in the maximum permitted leverage ratio (total debt divided by EBITDA [Earnings Before Interest, Taxes, Depreciation and Amortization]) as follows:

From: To:

4.5 times to 3.5 times on March 31, 2008 4.5 times to 4.0 times on March

31, 2009, and 4.0 times to 3.5

times on September 30, 2009

The amendment clarifies the definition of EBITDA to exclude up to $300 million of any restructuring charges incurred through June 30, 2009 and up to $500 million of any litigation charges -- less any litigation income recorded -- each year through June 30, 2009. In addition, the amendment changes the application of any term loan pre-payments from pro-rata across maturities to the chronological order of maturities.

The amended credit facility and resulting financial
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The birth of biotech: San Francisco, Boston, Geneva or Chicago?
2. Wicab to present BrainPort at Boston conference
3. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
4. Boston entrepreneur to enliven Milwaukee angel group
5. UW-Madisons Beebe wins scientific award
6. Researchers say scientific reporting needs more perspective, less hype
7. Wisconsin stands at the center of scientific efforts to avert flu epidemics
8. Growth prompts new location for scientific instrument manufacturer
9. UW stem cell guru outlines scientific and political future
10. Wisconsin biotech sector featured in scientific magazine
11. Scientific Protein Laboratories Acquired by New York firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 24, 2014 This research report ... Starch Based Plastics, Regenerated Cellulose, PCL), by Application ... and Forecasts to 2019”, defines and segments the ... forecast of its global volume and value. , ... spread through 178 Slides and in-depth TOC on ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in ... announced that its Board of Directors has appointed ... President and member of the Board effective immediately. ... expanded responsibilities within the company, including further developing ... commercialization, manufacturing and finance. , Dr. Carol ...
(Date:10/25/2014)... Great Barrington, MA (PRWEB) October 25, 2014 ... contamination control products, is pleased to announce the ... to achieve the highest level of contamination containment ... in ISO Class 3 and higher cleanroom environments, ... continuous filament polyester knit laundered wiper that continues ...
(Date:10/25/2014)... NEW YORK , Oct. 24, 2014 ... Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company advancing ... implemented a 1-for-50 reverse split of its common ... Friday, October 24, 2014. PlasmaTech,s common stock will ... number 72754H109 and temporary ticker symbol "ACCPD". After ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2
... April 8 ImQuest Life Sciences presented their ... their novel small molecule piperazine compound for the ... Therapeutics meeting held in Whistler, British Columbia. The ... lead microtubule inhibitor, IQP-0304. The piperazines demonstrate potent ...
... 8 Micromet, Inc. (Nasdaq: MITI ... for the treatment of cancer, inflammation and autoimmune ... the peer-reviewed Journal of Immunotherapy (1) demonstrating the ... to carcinoembryonic antigen (CEA) and to CD3 on ...
... 7 Pharmatech Oncology, Inc., a Research Management Organization ... companies at the Company Showcase during BIOZONA 2009 - ... Downtown on April 7th in Phoenix, Arizona.Matthew B. Wiener, ... during the first session of the conference. The ...
Cached Biology Technology:ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 2Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 3Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth 4Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA 2
(Date:10/22/2014)... by Northwestern Medicine® scientists helps explain how bipolar disorder ... new drug therapies to treat the mental illness. ... the same method recognized with the 2014 Nobel ... brain tissue from mice with bipolar-like behaviors. In the ... tiny "nanodomain" structures with concentrated levels of ANK3 -- ...
(Date:10/18/2014)... and stress-related psychiatric disorders are associated with ... molecular mechanisms underlying this relation are unknown. ... development of targeted preventive strategies and new ... This work is presented at the European ... an international group of researchers from Germany ...
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... million years ago, when the lineage of humans and ... turnips may have been one of the reasons. According ... of Minnesota and Richard Wrangham of Harvard University, the ... tubers must have sustained our ancestors who left the ...
... all likely to blame for poisoning the waters being drained from ... is leaving behind -- also owes its contamination to a source ... environments that made their way en masse into the water as ... Florida professor who has spent years studying the harmful contaminants that ...
... other non-terminal, debilitating conditions and diseases is both feasible ... such test on the approach in patients with advanced ... edition of the Proceedings of the National Academy of ... the potential to block the destructive inflammation process that ...
Cached Biology News:The roots of civilization trace back to ... roots 2Toxic flood lifts lid on common urban pollution problem 2Toxic flood lifts lid on common urban pollution problem 3Results of world's first gene therapy trial for arthritis show approach safe, feasible 2Results of world's first gene therapy trial for arthritis show approach safe, feasible 3Results of world's first gene therapy trial for arthritis show approach safe, feasible 4
MAb to Vasopressin Preservative: NaN3...
... Anti-AP-2 α, clone 8G8/5 GenBank Accession ... made human AP-2alpha/gamma fusion protein corresponding to ... 278-450 of human AP-2γ Formulation: 0.1M Tris-glycine, ... before the addition of glycerol to 30% ...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
Biology Products: